Key Developments: Boston Scientific Corp (BSX)

BSX on New York Consolidated

13.29USD
11 Jul 2014
Price Change (% chg)

$0.19 (+1.45%)
Prev Close
$13.10
Open
$13.01
Day's High
$13.31
Day's Low
$12.90
Volume
14,815,101
Avg. Vol
12,336,982
52-wk High
$14.08
52-wk Low
$9.38

Search Stocks

Latest Key Developments (Source: Significant Developments)

Boston Scientific Corp to acquire interventional division of Bayer AG
Thursday, 15 May 2014 07:00am EDT 

Boston Scientific Corp:Scientific Announces Definitive Agreement To Acquire Interventional Division Of Bayer AG.Acquisition for $415 mnl in cash, including fees for transitional services.Company expects to close the transaction in second half of 2014.  Full Article

Boston Scientific announces injunction lifted on catheter product Guidezilla - Reuters
Tuesday, 13 May 2014 11:36am EDT 

Boston Scientific Corp:Says U.S. appeals court has lifted a preliminary injunction placed on Boston Scientific Corp's catheter product Guidezilla by a lower court, as part of a patent fight with Vascular Solutions Inc.  Full Article

Boston Scientific to acquire IoGyn, Inc
Tuesday, 6 May 2014 05:26pm EDT 

Boston Scientific Corp:Signs a definitive agreement to acquire IoGyn, Inc., a pre-commercial stage company.Transaction is expected to close within days.  Full Article

Boston Scientific gives Q2 2014 guidance in line with analysts' estimates; reaffirms FY 2014 revenue guidance; raises FY 2014 EPS guidance
Tuesday, 29 Apr 2014 07:00am EDT 

Boston Scientific Corp:Continues to estimate revenue for FY 2014 to be in a range of $7.300 to $7.500 bln.Estimates FY 2014 income on GAAP basis in a range of $0.36 to $0.41 per share (compared to prior guidance of $0.35 to $0.40).Estimates FY 2014 adjusted earnings, excluding intangible asset impairment charges, acquisition and divestiture, litigation, and restructuring related charges and credits, discrete tax items, and amortization expense in range of $0.77 to $0.82 per share (compared to prior guidance of $0.75 to $0.80).Estimates sales for Q2 2014 in a range of $1.840 to $1.890 bln.Says Q2 2014 Adjusted earnings, excluding acquisition- and divestiture- and restructuring-related charges and amortization expense, are estimated in a range of $0.18 to $0.20 per share.FY 2014 revenue of $7.419 bln and EPS of $0.78 - Thomson Reuters I/B/E/S.Q2 2014 revenue of $1.867 bln and EPS of $0.20 - Thomson Reuters I/B/E/S.  Full Article

Boston Scientific Corp begins clinical trial of ACUITY X4 LV Pacing Leads and RELIANCE 4-FRONT ICD Leads
Tuesday, 22 Apr 2014 09:28am EDT 

Boston Scientific Corp:Conducted first implant in clinical trial of next generation ACUITY X4 left-ventricular (LV) pacing leads and RELIANCE(tm) 4-FRONT defibrillation (ICD) leads.Clinical trial is designed to establish safety and effectiveness of both lead families and is intended to support US FDA approval of these devices.  Full Article

Boston Scientific Corp announces FDA approval of innovative new defibrillators and heart failure devices
Tuesday, 15 Apr 2014 04:45pm EDT 

Boston Scientific Corp:Receives FDA approval for latest generation of defibrillators and heart failure devices designed to advance patient care.Newly approved devices include DYNAGEN MINI and INOGEN MINI ICDs, as well as the DYNAGEN X4 and INOGEN X4 CRT-Ds.X4 line of quadripolar CRT-Ds offers 70 percent more pacing options to address high capture thresholds and phrenic nerve stimulation effectively, along with largest battery capacity in industry.These newly approved devices continue Boston Scientific history of industry-leading projected longevity and six-year CRT-D warranty.  Full Article

Boston Scientific Corp introduces expect slimline needle for use during Endoscopic Ultrasound Fine Needle Aspiration Procedures
Monday, 7 Apr 2014 06:00pm EDT 

Boston Scientific Corp:Receives clearance from U.S. Food and Drug Administration (FDA) and CE Mark approval in Europe for Expect Slimline (SL) Needle, which is globally available for Endoscopic Ultrasound-Fine Needle Aspiration (EUS-FNA) procedures.Product's design incorporates extensive customer feedback and is used to collect tissue samples to diagnose and stage malignancies in organs adjacent to the gastrointestinal tract.Expect Slimline Needle is on contract with four leading group purchasing organizations.  Full Article

Boston Scientific Corp announces CE mark approval and first implants of ingevity MRI pacing leads
Friday, 14 Mar 2014 10:17am EDT 

Boston Scientific Corp:Says CE Mark approval and European market launch of INGEVITY family of magnetic resonance imaging (MRI) compatible pacing leads.  Full Article

Boston Scientific Corp receives CE Mark approval for REBEL platinum chromium coronary stent system
Wednesday, 12 Mar 2014 06:41pm EDT 

Boston Scientific Corp:Receives CE Mark approval for REBELplatinum chromium coronary stent system, the company's latest generation bare metal stent for the treatment of coronary artery disease (CAD).REBEL stent system offers physicians the same stent platform as Promus PREMIER drug eluting stent (DES) but without the everolimus drug.  Full Article

Boston Scientific Corp issues FY, Q1 2014 guidance; revenue guidance in line with analysts' estimates
Tuesday, 4 Feb 2014 07:01am EST 

Boston Scientific Corp:Estimates revenue for fiscal 2014 to be in a range of $7.300 bln to $7.500 bln.Estimates fiscal 2014 income on a GAAP basis in a range of $0.35 to $0.40 per share, and adjusted earnings, excluding acquisition and divestiture- and restructuring-related charges and amortization expense, in a range of $0.75 to $0.80 per share.Estimates sales for the first quarter of 2014 in a range of $1.755 bln to $1.805 bln.Estimates first quarter 2014 earnings on a GAAP basis in a range of $0.06 to $0.08 per share.Fiscal 2014 revenue of $7.411 bln and - Thomson Reuters I/B/E/S.First quarter 2014 revenue of $1.798 bln - Thomson Reuters I/B/E/S.  Full Article

Fitch Affirms Boston Scientific's IDR at 'BBB-'; Outlook Stable

(The following statement was released by the rating agency) CHICAGO, July 09 (Fitch) Fitch Ratings has affirmed Boston Scientific Corp.'s (NYSE: BSX) long-term IDR at 'BBB-' with a Stable Outlook. A full list of BSX's ratings follows at the end of this release. The rating action applies to approximately $4.25 billion of debt. KEY RATING DRIVERS: --Fitch expects BSX will operate with relatively stable leverage (total debt/EBITDA) of 2.3x-2.5x during the next 12 months, despite a challenging

Search Stocks